EVALUATION OF THE USE OF INTRAPERI-TONEAL CHEMOTHERAPY IN PERITONEAL CARCINOMATOSIS: A SINGLE CENTER EXPERIENCE

Introduction: Intraperitoneal chemotherapy (IPC) is a highly complex process of drug delivering with curative intent to carefully selected patients with advanced peritoneal carcinomatosis (PC). Objective: This study aimed to evaluate the use of IPC, in a real life setting, and assess the patients profile and outcomes. Method: A retrospective descriptive study was performed through the analysis of medical charts of patients submitted to hyperthermic intraperitoneal chemotherapy (HIPEC) or early postoperative intraperitoneal chemotherapy. Eligible patients presented ECOG performance status scores of 0 or 1 and peritoneal metastasis. Results: Twenty-six patients, with 72% of females, and the mean age of 55.19±11.21 were included. Ovarian cancer (50%), pseudomyxoma peritonei (34.6%), and colorectal cancer (15.3%) were the most common primary tumors. The individuals in the HIPEC group presented better ECOG score compared to the EPIC group (76.2% vs. 20%). In 92.3% of the cases, IPC was indicated as rescue therapy for relapsed tumors; in 57.6% of the cases, it was delivered after a second recurrence. Patients with pseudomyxoma peritonei (7.6%) received HIPEC as primary therapy after cytoreductive surgery. Only subjects with ovarian cancer receiver EPIC (19.2% of the included patients), all after a second recurrence. There was no difference in time to progression, considering HIPEC or EPIC treatments. Conclusion: Although complex, peritonectomy combined with IPC can be performed in referral centers with acceptable levels of morbidity and mortality.

 

MissingLinkText

No conflict of interest has been declared by the author(s).

Publication History

Article published online:
23 October 2019